Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $35.62M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | Flerie Inv... | flerie.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.02.2023 | - | $30M | Flerie Inv... |
| 08.10.2019 | - | $5.62M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.02.2023 | Microbial Immunotherapy Company Prokarium Raises $30 Million | Prokarium recently announced it raised $30 million. These are the details. Prokarium – a biopharmaceutical company leading the oncology field of microbial immunotherapy – announced it has raised $30 million in new funding. This funding roun... |
| 09.02.2023 | Microbial Immunotherapy Company Prokarium Raises $30M On Heels Of Ginkgo Bioworks Partnership | Prokarium CEO Kristen Albright.Prokarium |
| 09.02.2023 | Prokarium Raises $30M in Funding | Prokarium, a London, UK-based biopharmaceutical company which specializes in the oncology field of microbial immunotherapy, raised $30M in funding. The backers were not disclosed. The company intends to use the funds for clinical developmen... |
| 12.10.2021 | Wacker Chemie : Prokarium and Wacker Biotech Sign Manufacturing Contract for Prokarium's Microbial Immunotherapy for Bladder Cancer Patients | Go to selection pageBackForward Prokarium and Wacker Biotech Sign Manufacturing Contract for Prokarium's Microbial Immunotherapy for Bladder Cancer Patients Joint press release by WACKER and Prokarium London / Amsterdam, Oct 12, 2021 Prokar... |
| 08.10.2019 | Prokarium Raises £4.6M in Funding | Prokarium, a London, UK-based biotechnology company, received £4.59m in funding. The Wellcome Trust made the investment. The company intends to use the capital to fund two clinical trials of its lead programme, Entervax™, a bivalent vaccine... |
| - | Prokarium | “Pioneering Microbial Immunotherapies Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium... |